

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross® has confirmed that the shortage for Octreotide 10 mg/vial Injection (DIN 02503751), manufactured by Teva Canada Limited, has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 7, 2024**. The following grouping was removed from the Critical Supply Product List on **September 5, 2024**.

OCTREOTIDE ACETATE

10 MG / VIAL INJECTION

00002503751	OCTREOTIDE	TEV	\$ 990.6975
00002239323	SANDOSTATIN LAR	NOV	\$ 1,315.7400

Alberta Blue Cross has confirmed that the shortage for Octreotide 30 mg/vial Injection (DIN 02503786), manufactured by Teva Canada Limited, has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 7, 2024**. The following grouping was removed from the Critical Supply Product List on **September 5, 2024**.

OCTREOTIDE ACETATE

30 MG / VIAL INJECTION

00002503786	OCTREOTIDE	TEV	\$ 1,642.1400
00002239325	SANDOSTATIN LAR	NOV	\$ 2,180.9400

Alberta Blue Cross has confirmed that the shortage for pms-Diclofenac-Misoprostol 50 mg/200 mcg Enteric-Coated Tablet (DIN 02413469) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 10, 2024**. The following grouping was removed from the Critical Supply Product List on **September 11, 2024**.

DICLOFENAC SODIUM / MISOPROSTOL

50 MG / 200 MCG ENTERIC-COATED TABLET

00002341689	GD-DICLOFENAC / MISOPROSTOL 50	GMD	\$ 0.3149
00002413469	PMS-DICLOFENAC-MISOPROSTOL	PMS	\$ 0.3149
00001917056	ARTHROTEC-50	PFI	\$ 0.7449

continued next page

PHARMACY BENEFACT

continued from previous page

Alberta Blue Cross has confirmed that the shortages for Apo-Valacyclovir 500 mg Caplet (DIN 02295822), Auro-Valacyclovir 500 mg Tablet (DIN 02405040), Mylan-Valacyclovir 500 mg Caplet (DIN 02351579), pms-Valacyclovir 500 mg Caplet (DIN 02298457) and Valacyclovir 500 mg Tablet (DIN 02454645), manufactured by Sanis Health Inc., have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 18, 2024**. The following grouping was removed from the Critical Supply Product List on **September 18, 2024**.

VALACYCLOVIR

500 MG TABLET

00002295822	APO-VALACYCLOVIR	APX	\$ 0.6198
00002405040	AURO-VALACYCLOVIR	AUR	\$ 0.6198
00002440598	JAMP-VALACYCLOVIR	JPC	\$ 0.6198
00002441454	JAMP-VALACYCLOVIR	JPC	\$ 0.6198
00002351579	MYLAN-VALACYCLOVIR	MYP	\$ 0.6198
00002298457	PMS-VALACYCLOVIR	PMS	\$ 0.6198
00002347091	SANDOZ VALACYCLOVIR	SDZ	\$ 0.6198
00002357534	TEVA-VALACYCLOVIR	TEV	\$ 0.6198
00002442000	VALACYCLOVIR	SIV	\$ 0.6198
00002454645	VALACYCLOVIR	SNS	\$ 0.6198
00002219492	VALTREX	GSK	\$ 3.8882

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

